Key Specifications Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|R, H, M||WB, IHC||M||Purified||Monoclonal Antibody|
|Presentation||Purified mouse monoclonal IgG2bκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.|
|Safety Information according to GHS|
|Storage and Shipping Information|
|Storage Conditions||Stable for 1 year at 2-8°C from date of receipt.|
|Material Size||100 µg|
|Anti-Mena, clone A351F7D9 - 2192292||2192292|
|Anti-Mena, clone A351F7D9 - NRG1777071||NRG1777071|
|Anti-Mena, clone A351F7D9 -2500712||2500712|
|Anti-Mena, clone A351F7D9 -2581269||2581269|
|Anti-Mena, clone A351F7D9 -2608456||2608456|
|Anti-Mena, clone A351F7D9 -2691335||2691335|
|Anti-Mena, clone A351F7D9 -2705083||2705083|
|Reference overview||Application||Pub Med ID|
|Endophilin, Lamellipodin, and Mena cooperate to regulate F-actin-dependent EGF-receptor endocytosis. |
Vehlow, Anne, et al.
EMBO J., (2013) 2013
The epidermal growth factor receptor (EGFR) plays an essential role during development and diseases including cancer. Lamellipodin (Lpd) is known to control lamellipodia protrusion by regulating actin filament elongation via Ena/VASP proteins. However, it is unknown whether this mechanism supports endocytosis of the EGFR. Here, we have identified a novel role for Lpd and Mena in clathrin-mediated endocytosis (CME) of the EGFR. We have discovered that endogenous Lpd is in a complex with the EGFR and Lpd and Mena knockdown impairs EGFR endocytosis. Conversely, overexpressing Lpd substantially increases the EGFR uptake in an F-actin-dependent manner, suggesting that F-actin polymerization is limiting for EGFR uptake. Furthermore, we found that Lpd directly interacts with endophilin, a BAR domain containing protein implicated in vesicle fission. We identified a role for endophilin in EGFR endocytosis, which is mediated by Lpd. Consistently, Lpd localizes to clathrin-coated pits (CCPs) just before vesicle scission and regulates vesicle scission. Our findings suggest a novel mechanism in which Lpd mediates EGFR endocytosis via Mena downstream of endophilin.
|SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. |
Han, K; Holder, JL; Schaaf, CP; Lu, H; Chen, H; Kang, H; Tang, J; Wu, Z; Hao, S; Cheung, SW; Yu, P; Sun, H; Breman, AM; Patel, A; Lu, HC; Zoghbi, HY
Nature 503 72-7 2013
Mutations in SHANK3 and large duplications of the region spanning SHANK3 both cause a spectrum of neuropsychiatric disorders, indicating that proper SHANK3 dosage is critical for normal brain function. However, SHANK3 overexpression per se has not been established as a cause of human disorders because 22q13 duplications involve several genes. Here we report that Shank3 transgenic mice modelling a human SHANK3 duplication exhibit manic-like behaviour and seizures consistent with synaptic excitatory/inhibitory imbalance. We also identified two patients with hyperkinetic disorders carrying the smallest SHANK3-spanning duplications reported so far. These findings indicate that SHANK3 overexpression causes a hyperkinetic neuropsychiatric disorder. To probe the mechanism underlying the phenotype, we generated a Shank3 in vivo interactome and found that Shank3 directly interacts with the Arp2/3 complex to increase F-actin levels in Shank3 transgenic mice. The mood-stabilizing drug valproate, but not lithium, rescues the manic-like behaviour of Shank3 transgenic mice raising the possibility that this hyperkinetic disorder has a unique pharmacogenetic profile.